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Background: Visual inspection with acetic acid (VIA) to identify and treat pre-cancerous lesions is effective for
cervical cancer prevention. Screening programs also facilitate screening and diagnosis of invasive cancers that must
be referred for radiation therapy or chemotherapy. This study compared characteristics of women diagnosed with
invasive cervical cancer by a VIA screening program who did and did not follow up for treatment and who did and
did not complete treatment at the Ocean Road Cancer Institute (ORCI), Dar es Salaam, Tanzania.
Methods: We conducted a retrospective cohort study of ORCI screening referrals from the period November 2002
to June 2011. Women referred for treatment of invasive disease (n = 980) were identified from an existing database
of all women attending the screening clinic during this period (n = 20,131) and matched to a dataset of all cervical
cancer patients attending ORCI in this period (n = 8,240). Treatment information was abstracted from patient
records of women who followed up. Records of a random sample (n = 333) of unscreened patients were reviewed
for disease stage.
Results: Of the 980 women referred women, 829 (84.6%) sought treatment. Most of those women (82.8%)
completed their prescribed radiation. Lower disease stage, having a skilled occupation, residence in Dar es Salaam,
and younger age were independently associated with loss to follow-up. Higher disease stage, residence in Dar es
Salaam, older age, and later year of first treatment appointment were independently associated with incomplete
treatment among those who followed up. Significantly more screened women had stage 1 disease (14.0%) than
unscreened women (7.8%).
Conclusions: Most women referred from the screening clinic completed treatment for their cancer at ORCI. Some
of those lost to follow-up may have sought treatment elsewhere. In most cases, the screening clinic appears to
facilitate diagnosis and treatment, rather than screening, for women with invasive cervical cancer.
Keywords: Cervical cancer, Screening, Visual inspection with acetic acid, Referral patterns, Radiation therapy,
Tanzania* Correspondence: amr.soliman@unmc.edu
2University of Nebraska Medical Center College of Public Health, Omaha, NE,
USA
Full list of author information is available at the end of the article
© 2014 Gard et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly credited.
Gard et al. BMC Public Health 2014, 14:910 Page 2 of 11
http://www.biomedcentral.com/1471-2458/14/910Background
East Africa has the highest cervical cancer burden
worldwide [1]. In Tanzania, it is the most common
cancer in women, with an estimated annual incidence
of 50.9 cases per 100,000 and mortality of 37.5 women
per 100,000 in 2008 [1].
Although Pap smear is the most commonly used cervical
screening modality in the developed world, it requires
substantial medical infrastructure, training, and financial
resources to implement, and therefore is not feasible for
widespread application in most developing countries [2].
A simpler, more cost-effective [2] screening method is
visual inspection with acetic acid (VIA), which has been
shown to be accurate for detection of precancerous and
cancerous cervical lesions [3] and effective for cancer
prevention in large, randomized studies conducted in
developing countries [4,5].
The benefits of VIA are primarily from pre-clinical detec-
tion of pre-cancerous lesions treatable with cryotherapy,
LEEP, or cold-knife conization, preventing these lesions
from progressing to invasive cancer [2,5]. However,
VIA screening programs also facilitate detection of
asymptomatic invasive cervical cancers and diagnosis
of symptomatic invasive cancers, through both VIA
itself and the provision of basic gynecological care by
competent health workers. These cancers must be re-
ferred for surgery, radiation therapy, or chemotherapy.
We have identified no study to date that has provided a
comprehensive evaluation of the outcomes of women
with invasive cancer detected or diagnosed by a VIA
screening program.
Several studies have reported the percentage of women
diagnosed with invasive cervical cancer at screening [6-10],
with at least four studies offering some information about
the treatment received by women referred from screening
[11-14]. One study compared the stage of invasive cancer
diagnosed in screened and unscreened women [5]. In
Mali, 73.4% of 497 women referred from screening re-
ceived some treatment – 35.0% radical hysterectomy,
34.4% cyclophosphamide chemotherapy, and 4.0% radi-
ation (none completed a full course) [11]. In Angola, 80.7%
of 57 women received some treatment – 71.9% surgery or
radiation and 8.8% “less-appropriate treatment” [13].
In a randomized study in south India, 82.6% of 69
screening-detected invasive cancers were treated [15].
This is the only study to assess predictors of compliance
with treatment after VIA, although the analysis combined
cervical intraepithelial neoplasia and invasive cancer.
The authors found younger age, practicing some form of
contraception, and having a high-grade precursor lesion
or invasive cancer (vs. a low-grade precursor lesion) were
positively and independently associated with treatment
compliance [15]. This study also found that significantly
more screened than unscreened women were diagnosedwith stage 1 disease (19.8% vs. 10.1%, p = 0.015) [5], an
important benefit of screening.
The fourth study demonstrated the feasibility and accur-
acy of visual inspection and clinic-based treatment of pre-
cancerous lesions at the Ocean Road Cancer Institute
(ORCI) in Dar es Salaam, the largest city in Tanzania [12].
Women were actively recruited from Dar es Salaam for
participation, but this was not a population-based effort.
Compiling data from November 2002 to August 2007, 1.9%
of the 10,378 women included in the analysis had invasive
cancer and 96% were treated [12]. Following the comple-
tion of that study in August 2007, ORCI has continued to
offer screening on a daily basis [12], but women are gener-
ally not actively recruited for screening. This screening pro-
gram presented an opportunity to explore the referral,
treatment, and disease stage patterns of women diagnosed
with invasive cervical cancer by a VIA screening program
across an extended time period.
We conducted a retrospective cohort study building
upon the ORCI study just described. We compared
characteristics of women referred for treatment who
followed up to those lost to follow-up, of women who
completed treatment to those who did not, and the
cancer stage of screened and unscreened women who
sought treatment. We hypothesized age, disease stage,
distance from treatment facilities, socioeconomic status,
and reproductive factors would influence follow-up from
screening to treatment and treatment completion. We
also hypothesized women who attended the screening
clinic would be more likely to be diagnosed with stage 1
disease than unscreened women.
Methods
This retrospective cohort study was based on medical
records from the ORCI cervical cancer screening clinic
and the ORCI cancer treatment clinic (Figure 1), the
only specialized cancer treatment center in Tanzania.
Screening and referral populations
Each visit at the ORCI screening clinic is documented
with a standardized paper reporting form and includes a
screening clinic serial number, interview date, name, age,
place of residence (municipality, district, or region), occupa-
tion, education, marital status, last menstrual period, age at
marriage, gravidity, and screening clinic visit results. These
forms were routinely entered into an EpiInfo database
by ORCI staff, representing visits completed from the
initiation of the screening program in November 2002
to June 2011 (n = 20,131). Only a couple of patients
attended more than once during this period, so each
form represents a unique person.
Since not all histopathology results had been entered into
this database, especially in later years, we digitized the
histopathology results from biopsy log books covering the
ORCI Paents
-
-
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ORCI Screening
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Referred Paents
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Figure 1 Datasets.
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with the screening clinic database. The log book covering
November 2002 to March 2005 was not available, but it
appeared histopathology results from this time period had
already been entered in the EpiInfo database. Of 1,001 re-
sults in these books, 788 were matched with the screening
clinic database after eliminating duplicates, non-cervix bi-
opsies, and results from outreach screening programs not
conducted at ORCI.
The subset of women likely referred for treatment of
invasive disease was identified and constitutes the refer-
ral population. As referrals from ORCI screening to
treatment are not formally tracked, we developed a case
definition to infer who was referred based on screening
results and biopsy records. At ORCI, the screening clinic
continues to operate under the protocols used in the ori-
ginal VIA screening study described above. Therefore,
most women screened by VIA also undergo colposcopy,
and most women with abnormal colposcopy findings are
also biopsied for histopathology. A woman was consid-
ered referred (n = 980) if she was in the screening clinic
database and had listed a final diagnosis of invasive can-
cer, a stage of invasive disease, a histopathology result of
invasive cancer, or a colposcopy diagnosis of invasive
cancer (unless contradicted by a histopathology result).
While histopathology is the gold standard for diagnosis,
not all patients with clinically obvious cancer receive a
biopsy and not all biopsies are expeditiously processed,
so we could not rely on histopathology alone to deter-
mine who was referred.
Cervical cancer patient population
A dataset of all cervical cancer patients attending ORCI
in this period was created by digitizing annual patient log
books. The resulting dataset included medical records
from November 2002 to October 2011, five months afterthe last observation in the ORCI screening clinic database,
based on the expected limit of typical follow-up times.
The 2006 patient log book was unavailable, so every pa-
tient record from 2006 (n = 2,549) was manually reviewed
to identify cervical cancer cases. To improve the quality of
the patient dataset, we identified 1,819 records where the
log book was unclear on the cancer type. Of these records,
1,708 were located (93.9%) and reviewed to check for a
cervical cancer diagnosis, which identified 200 additional
cervical cancer cases (11.7%).
Matching referrals to cervical cancer patients
To determine which women who attended the ORCI
screening clinic and were referred for treatment of invasive
cervical cancer followed up for at least one ORCI treatment
clinic appointment, a SAS algorithm was developed to
identify matches between referrals (n = 980) and the ORCI
cervical cancer patient dataset (n = 8,240). All possible
referral-patient combinations were generated, and then
compared on name (asymmetric spelling distance), age,
follow-up time, and place of residence. This process iden-
tified candidate matches for manual review (n = 7,198),
while not excluding unlikely, but true matches. Manual re-
view of potential matches identified a subset of 944 prob-
able matches, of which 829 were determined to be true
matches: 765 (92.3%) confirmed by reviewing patient re-
cords and 64 whose records were not reviewed but were
extremely likely matches based on available information. Of
the 765, 82.9% were confirmed by the presence of an ORCI
screening clinic card in the record, which lists the screening
clinic serial number, patient identifiers, screening clinic visit
results, and follow-up instructions. 4.7% were missing the
card but included the screening clinic serial number in the
record, and 12.4% had neither. The follow-up status of
those with neither was carefully reviewed to confirm a true
match between screening and treatment datasets.
Gard et al. BMC Public Health 2014, 14:910 Page 4 of 11
http://www.biomedcentral.com/1471-2458/14/910Treatment assessment
Treatment data were abstracted for the 765 matches for
whom a patient record was reviewed. Follow-up time
was the difference between the screening clinic visit date
and the first treatment appointment date. Treatment
duration was the date difference between the first and
last recorded clinical note. Attendance at another health
facility before screening was assessed by clinical notes
and presence of documents from other health facilities
dated prior to the screening clinic visit.
The radiation dose prescribed (Gy), radiation dose
completed (Gy), brachytherapy doses completed, and
receipt of at least one dose of chemotherapy were ab-
stracted from standardized treatment documentation
forms. Radiation was considered complete if the
woman received at least the dose she was prescribed,
or if she completed at least 75% of her prescribed dose
and her treatment duration was longer than 180 days
(to account for prescriptions that were likely reduced).
Women with no radiation prescription listed (n = 13)
were considered to not have completed prescribed ra-
diation because all had stage 1B disease or higher.
The screening clinic disease stage was from the screening
clinic visit or, if missing, the clinical note of the first treat-
ment appointment where follow-up time was no more than
15 days. The treatment clinic disease stage was from the
clinical note of the first treatment appointment or, if miss-
ing, the screening clinic visit where follow-up time was no
more than 15 days.
Disease stage comparison
Records of a random sample (n = 333) of unscreened pa-
tients (n = 7,438) were successfully reviewed for disease
stage, as assessed at first treatment appointment.
Data analysis
The data were analyzed in SAS 9.3 (SAS Institute,
Cary, NC). We compared characteristics of referred
and non-referred women in the screening population
using chi-squared and Mann-Whitney U tests. We
then compared characteristics of women who followed
up for at least one treatment clinic appointment to those
lost to follow-up using chi-squared, Mann-Whitney U,
and t-tests, followed by multivariable analysis with lo-
gistic regression. Among those who followed up, we
compared characteristics of those who did and did not
complete their prescribed radiation with the same
methods. Finally, we assessed disease stage among
women who attended the screening clinic and unscreened
women by logistic regression.
The study was approved by the University of Michigan
Health Sciences and Behavioral Sciences IRB and by
the ORCI Academic, Research, Publications and Ethics
Committee.Results
Among the 20,131 women who attended the screening
clinic, 980 (4.9%) were diagnosed with invasive cancer
(Table 1). This proportion increased over the study
period, from less than 2% in 2002 and 2003 to more
than 6% after 2005. Women diagnosed with invasive
cancer were significantly more likely to be housewives
or manual laborers, uneducated, widowed or separated,
and to have had their last menstrual period more than
12 months ago. They were also significantly older, had
younger age at marriage, and higher gravidity.
Among the 980 with invasive cancer, 829 (84.6%)
followed up at ORCI for at least one treatment clinic
appointment (Table 2). This proportion did not change
significantly over the study period. The mean and me-
dian follow-up times were 26 and 14 days, respectively.
The median follow-up time increased significantly over
the study period (Figure 2), and was longer for women
from Dar es Salaam (Figures 2 and 3). Women with a
skilled occupation, more than primary education, last
menstrual period less than 12 months ago, younger age,
lower gravidity, residence in Dar es Salaam, and earlier
disease stage at screening were significantly less likely to
follow up. Marital status and age at marriage were not
significantly associated with follow-up status.
In multivariable models, education, timing of last men-
strual period, gravidity, and place of residence were no
longer significantly associated with follow-up status after
adjustment for age and disease stage (Table 3). In a final
model including age, disease stage, occupation, and place
of residence, women with a skilled occupation were half as
likely (OR = 0.51, 95% CI 0.28-0.91) to have followed up
compared to housewives. Each one-unit increase in disease
stage was associated with a 2.70 fold (95% CI 1.87-3.89)
increase in the odds of follow-up. Each ten-year increase in
age was associated with a 19 percent increase (OR = 1.19,
95% CI 0.96-1.48) in the odds of follow-up, although the CI
included one. Residence outside of Dar es Salaam was asso-
ciated with a 1.47 fold (95% CI 0.87-2.48) increase in the
odds of follow-up compared to women from Dar es Salaam,
but again, the CI included one.
Of the 829 women who followed up for at least one
treatment clinic appointment, 765 were assessed for
treatment received. Of these, 687 (89.8%) received at
least some radiation, brachytherapy, or chemotherapy
(Table 4) and 633 (82.8%) completed their prescribed
dose of radiation (Table 5). Of all women diagnosed
with invasive disease at screening, women prescribed
less than 40Gy radiation and those with later disease
stage at treatment were significantly less likely to
complete radiation. Women who were older, treated in
a later study year, and resided in Dar es Salaam were
less likely to completion radiation, but these bivariable
associations were not significant.
Table 1 Demographic characteristics by invasive disease
status among 20,131 women seen November 2002 to
June 2011
No invasive
cervical cancer
Invasive
cervical cancer
N/mean %/SD N/mean %/SD
Total 19,151 95.1 980 4.9
Occupation
Housewife 9,847 51.4% 755 77.0%
p < 0.0001*
Manual 727 3.8% 64 6.5%
Technical 235 1.2% 2 0.2%
Office going 2,126 11.1% 32 3.3%
Teaching 1,332 7.0% 11 1.1%
Professional 1,217 6.4% 3 0.3%
Business 3,529 18.4% 100 10.2%
Other 101 0.5% 9 0.9%
Missing 37 0.2% 4 0.4%
Education
None 1,723 9.0% 411 41.9%
p < 0.0001*
Primary 10,365 54.1% 481 49.1%
Middle 4,524 23.6% 63 6.4%
High School 628 3.3% 9 0.9%
College 1,843 9.6% 9 0.9%
Missing 68 0.4% 7 0.7%
Marital status
Married/regular
partner
15,551 81.2% 630 64.3%
p < 0.0001*Widowed 1,368 7.1% 207 21.1%
Separated 1,402 7.3% 131 13.4%
Other 677 3.5% 6 0.6%
Missing 153 0.8% 6 0.6%
Last menstrual
period
<12 months ago 15,962 83.3% 530 54.1%
p < 0.0001*
>12 months ago 3,060 16.0% 436 44.5%
Missing 129 0.7% 14 1.4%
Age 39.4 10.0 50.5 12.9 p < 0.0001**
Missing 48 3
Age at marriage 21.4 4.4 19.0 4.3 p < 0.0001**
Missing 1,966 94
Gravidity 3.8 2.7 6.3 3.2 p < 0.0001**
Missing 731 15
Year of screening
2002 549 2.9% 10 1.0%
p < 0.0001*
2003 4,681 24.4% 77 7.9%
2004 2,465 12.9% 82 8.4%
2005 1,570 8.2% 81 8.3%
Table 1 Demographic characteristics by invasive disease
status among 20,131 women seen November 2002 to
June 2011 (Continued)
2006 1,089 5.7% 92 9.4%
2007 1,610 8.4% 134 13.7%
2008 1,698 8.9% 144 14.7%
2009 2,258 11.8% 143 14.6%
2010 2,363 12.3% 155 15.8%
2011 866 4.5% 58 5.9%
Missing 2 0.0% 4 0.4%
*Chi-squared test.
**Mann-Whitney U test (t approximation).
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place of residence, and treatment year, each one-unit in-
crease in disease stage was associated with a 28 percent
decrease (OR = 0.72, 95% CI 0.55-0.96) in the odds of ra-
diation completion (Table 6). Each two-year increase in
treatment year was associated with a 15 percent decrease
(OR = 0.85, 0.72-1.00, p = 0.0499) in the odds of radiation
completion. Residence outside of Dar es Salaam was asso-
ciated with a 1.46 fold (95% CI 0.99-2.15) increase in the
odds of radiation completion compared to women from
Dar es Salaam, however the CI included one. A ten-year
increase in age was associated with a 13 percent decrease
(OR = 0.87, 95% CI 0.75-1.01) in the odds of radiation
completion, but the CI included one.
The median treatment duration was 380 days (mean 600,
standard deviation 615) among those who completed their
prescribed radiation, and 0 days (mean 40, standard devi-
ation 116) among those who did not complete their pre-
scribed radiation (0 indicating completion of only the initial
appointment at the treatment clinic). Follow-up time did
not significantly differ between those who did and did not
complete their prescribed radiation. All women assessed
were symptomatic at their first appointment. A quarter
(23%) of women who followed up had attended another
health facility before attending the ORCI screening clinic
regarding their symptoms.
Among the sample of unscreened women who presented
for treatment at ORCI, 7.8% (26/333) had stage 1 disease.
Among women referred for treatment from the screening
clinic who had stage information available, 14.0% (101/721)
had stage 1 disease. Attending the screening clinic was
associated with 1.61 (95% CI 1.01-2.56) times the odds
of stage 1 disease, after adjusting for age and place of
residence (Table 7).
Discussion
This study is the first study to evaluate treatment comple-
tion following referral from a VIA screening program for
invasive cervical cancer. Our results show a high propor-
tion of women referred from the screening clinic followed
Table 2 Demographic and disease characteristics by
follow-up status among 980 women referred for treatment
Lost to
follow-up
Followed up
at ORCI
N/mean %/SD N/mean %/SD
Total 151 15.4 829 84.6
Occupation
Housewife 103 68.2% 652 78.6%
p = 0.0008*Manual 8 5.3% 56 6.8%
Skilled/Other 40 26.5% 117 14.1%
Missing 0 0.0% 4 0.5%
Education
None 48 31.8% 363 43.8%
p = 0.0042*Primary 83 55.0% 398 48.0%
>Primary 20 13.2% 61 7.4%
Missing 0 0.0% 7 0.8%
Marital status
Married/regular
partner
108 71.5% 522 63.0%
p = 0.0557*
Widow/separated/
other
43 28.5% 301 36.3%
Missing 0 0.0% 6 0.7%
Last menstrual period
<12 months ago 96 63.6% 434 52.4%
p = 0.0107*
>12 months ago 53 35.1% 383 46.2%
Missing 2 1.3% 12 1.4%
Age 46.9 13.4 51.1 12.7 p = 0.0002***
Age at marriage 19.1 3.7 18.9 4.4 p = 0.2271**
Gravidity 5.6 3.2 6.4 3.2 p = 0.0022***
Year of screening
2002-2003 13 8.6% 74 8.9%
p = 0.4405†
2004-2005 23 15.2% 140 16.9%
2006-2007 35 23.2% 191 23.0%
2008-2009 42 27.8% 245 29.6%
2010-2011 38 25.2% 175 21.1%
Missing 0 0.0% 4 0.5%
Place of residence
Dar es Salaam 96 63.6% 417 50.3%
p = 0.0027*
Other Region 55 36.4% 412 49.7%
Screening clinic
disease stage
1 32 21.2% 69 8.3%
p < 0.0001†
2 36 23.8% 313 37.8%
3 13 8.6% 248 29.9%
4 0 0.0% 10 1.2%
Missing 70 46.4% 189 22.8%
*Chi-squared test.
**Mann-Whitney U test (t approximation).
***t-test with equal variances.
†Mantel-Haenszel chi-squared test for trend.
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estimate at least 76% of women diagnosed with invasive
disease at the ORCI screening clinic received at least some
treatment, and at least 70% completed their prescribed
radiation. These proportions are likely higher, were we
to account for treatment received elsewhere.
Lower disease stage, having a skilled occupation, residence
in Dar es Salaam, and younger age were independently asso-
ciated with loss to follow-up. Higher disease stage, residence
in Dar es Salaam, older age, and later year of first treatment
appointment were independently associated with incom-
plete treatment among those who followed up. Significantly
more screened women had stage 1 disease (14.0%) than
unscreened women (7.8%). In most cases, the screening
clinic appears to facilitate diagnosis and treatment, rather
than screening, for women with invasive cervical cancer.
We found that more advanced disease stage was associ-
ated with greater likelihood of follow-up. However, women
with more advanced disease stage were less likely to
complete their prescribed radiation. The south Indian
trial suggested invasive cancer (all stages combined) was
associated with a greater likelihood of treatment com-
pletion compared to low grade, pre-cancerous lesions
(OR = 1.55, 95% CI 0.7-3.6) [15], but this is not directly
comparable to our study because we did not include women
with pre-cancerous lesions. Furthermore, the south Indian
trial did not separately assess follow-up and treatment com-
pletion among those who followed up, as in our study.
Some of those lost to follow-up likely received treatment
elsewhere. Women with skilled occupations were half as
likely to follow up for treatment as housewives or manual
laborers. This likely reflects that women with higher
socioeconomic status have the means to travel outside of
Tanzania for cancer treatment, typically to Kenya, South
Africa, or India. Occupation was not, however, associated
with completion of radiation among those who did follow
up at ORCI. This finding suggests finances were not a sig-
nificant barrier to treatment, which is government funded
and provided free of charge in Tanzania. The south Indian
trial also found occupation was not associated with com-
pliance to treatment, which was free of charge [15].
ORCI is the only specialized cancer treatment center
in Tanzania, so it attracts patients from every region of
the country. Nearly half of women with invasive disease
were from outside of Dar es Salaam, and they were more
likely to both follow up and complete treatment com-
pared to women residing in Dar es Salaam. Residents of
other regions also presented for follow-up sooner than
women from Dar es Salaam and were less likely to have
stage 1 disease. The reasons for these differences by region
should be explored in future studies.
Older women were more likely to follow up, but were
less likely to complete radiation therapy, although these
associations were not significant in multivariable analysis.
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Figure 2 Median follow-up time by year.
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follow-up among the youngest patients, while the effect
on radiation appears to be driven by incomplete treatment
among the oldest patients (results not shown).
Although the proportion of women who followed up
did not change significantly over the study period, the
data suggest that the proportion of women completing
radiation decreased over time. The volume of patients
(all cancers) increased 64% over the study period, from
1,897 in 2002 to 3,102 in 2011, placing an increased bur-
den on radiation therapy equipment, which sometimes
broke down. Scheduling radiation therapy also became
increasingly difficult, since many patients required 15
to 20 sessions to complete their prescribed dose. The
increased patient volume may also account for the
increase in follow-up time seen over the study period,
since follow-up time is a function of both provider
(supply) and patient (demand) factors.
The assessment of treatment focused on radiation
because it was most consistently documented and is
the primary cervical cancer treatment modality at ORCI.
However, for patients treated with curative intent, radiation
is supplemented by brachytherapy when the machine isFigure 3 Histogram of follow-up time.operable, and chemotherapy in some cases. Only women
who completed their prescribed radiation went on to re-
ceive brachytherapy, per ORCI guidelines. Less than one-
fifth of women received at least one dose of chemotherapy,
and this was often for palliation.
The proportion of screened women diagnosed with
invasive cancer (4.9%) was higher than reported in other
African studies (3.5% in Mali [11], 1.9% in Zambia [9],
and 0.6% in Angola [13]). This difference likely reflects
both the high burden of cervical cancer in Tanzania, as
well as the program design. While the absolute number
of cervical cancer cases referred from the screening
clinic each year did double from 2003-2010, the increasing
proportion of women diagnosed with invasive disease was
also a function of significant changes in the number attend-
ing the screening clinic over time. Initially, considerable
efforts were taken to recruit women from the community
for screening [12], with 4,758 women screened during the
first full year of the program (2003). The lowest proportion
of invasive disease was seen in that year, since many of the
women screened would not have attended unless invited.
In contrast, women with invasive cervical cancer or another
gynecologic problem are typically symptomatic and more
Table 3 Logistic regression of follow-up status among 980 women referred for treatment
Crude Age-adjusted Age, stage-adj. Final Model*
OR CI OR CI OR CI OR CI
Occupation
Housewife 1 1 1 1
Manual 1.11 0.51-2.39 1.16 0.53-2.50 1.04 0.35-3.14 0.96 0.32-2.92
Skilled/Other 0.46 0.31-0.70 0.58 0.38-0.90 0.47 0.27-0.84 0.51 0.28-0.91
Education
None 1 1 1
Primary 0.63 0.43-0.93 0.82 0.54-1.24 0.99 0.56-1.75
>Primary 0.40 0.22-0.73 0.53 0.29-0.99 0.68 0.30-1.54
Marital status
Married/regular partner 1 1 1
Widow/separated/other 1.45 0.99-2.12 1.21 0.81-1.80 1.09 0.63-1.88
Last menstrual period
<12 months ago 1 1 1
>12 months ago 1.60 1.11-2.30 1.01 0.63-1.62 1.12 0.60-2.09
Age
Continuous (10 year) 1.31 1.13-1.52 1.31 1.07-1.61 1.19 0.96-1.48
Age at marriage
Continuous 0.99 0.95-1.03 1.00 0.96-1.04 1.00 0.94-1.06
Gravidity
Continuous 1.09 1.03-1.16 1.06 0.99-1.13 1.07 0.97-1.17
Place of residence
Dar es Salaam 1 1 1 1
Other Region 1.73 1.21-2.47 1.57 1.09-2.27 1.62 0.97-2.70 1.47 0.87-2.48
Screening clinic disease stage
Continuous 3.16 2.21-4.52 2.91 2.02-4.18 2.70 1.87-3.89
*Final model adjusted for age, screening clinic disease stage, place of residence, and occupation.
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http://www.biomedcentral.com/1471-2458/14/910likely to attend the screening clinic uninvited. These women
represented a larger proportion of screened women in later
years, when there were fewer screening promotion efforts in
the community.
It is clear that women with symptomatic cervical cancer
are attending the ORCI screening clinic seeking a proper
diagnosis, rather than screening. They have often been
treated for symptoms of cervical cancer at the regional
and local level, delaying a formal diagnosis and initiationTable 4 ORCI treatment received among 765* women with in
No chemotherapy
Brachytherapy doses
Prescribed radiation 0 1 2-3
Received none 78 0 0
Partially completed 50 0 0
Completed 445 3 49
Total 573 3 49
*64/829 missing ORCI treatment data.of appropriate therapy in many cases. In this study, all
women who followed up were symptomatic, and a quar-
ter of women who followed up had already been seen
elsewhere. ORCI’s VIA screening program has directly
contributed to development of the human capital and
clinic infrastructure necessary for not only VIA screen-
ing, but also for providing basic gynecologic care and
referral. With these resources, women can be efficiently
directed to appropriate care.vasive cervical cancer who followed up for treatment
≥1 dose chemotherapy
Brachytherapy doses
Total 0 1 2-3 Total
78 1 0 0 1
50 3 0 0 3
497 101 4 31 136
625 105 4 31 140
Table 5 Patient characteristics by radiation completion
among 829 women who followed up for treatment at ORCI
Did not
complete
prescribed
radiation
Completed
prescribed
radiation
N/mean %/SD N/mean %/SD
Total 132 17.3 633 82.8
Missing n = 64
Occupation
Housewife 106 80.3% 499 78.8%
p= 0.2996*Manual 12 9.1% 41 6.5%
Skilled/Other 14 10.6% 93 14.7%
Education
None 64 48.5% 278 43.9%
p= 0.5405*Primary 57 43.2% 308 48.7%
>Primary 10 7.6% 45 7.1%
Missing 1 0.8% 2 0.3%
Marital status
Married/regular
partner
81 61.4% 400 63.2%
p= 0.6607*
Widow/separated/
other
51 38.6% 231 36.5%
Missing 0 0.0% 2 0.3%
Last menstrual period
<12 months ago 66 50.0% 332 52.4%
p= 0.5802*
>12 months ago 65 49.2% 294 46.4%
Missing 1 0.8% 7 1.1%
Age 53.2 14.2 51.0 12.5 p = 0.1027†
Age at marriage 19.2 5.8 18.8 3.8 p = 0.9204**
Gravidity 6.2 3.4 6.5 3.1 p = 0.3472***
Year of first
treatment
appointment
2002-2003 6 4.5% 61 9.6%
p = 0.0571‡
2004-2005 24 18.2% 107 16.9%
2006-2007 23 17.4% 145 22.9%
2008-2009 43 32.6% 177 28.0%
2010-2011 36 27.3% 143 22.6%
Place of residence
Dar es Salaam 74 56.1% 302 47.7%
p= 0.0808*
Other Region 58 43.9% 331 52.3%
Treatment clinic
disease stage
1 9 6.8% 67 10.6%
p = 0.0221‡
2 58 43.9% 333 52.6%
3 57 43.2% 212 33.5%
4 5 3.8% 21 3.3%
Missing 3 2.3% 0 0.0%
Table 5 Patient characteristics by radiation completion
among 829 women who followed up for treatment at ORCI
(Continued)
Attended another
health facility
before screening
Yes 25 18.9% 150 23.7%
p= 0.2528*
No 106 80.3% 483 76.3%
Missing 1 0.8% 0 0.0%
Prescribed ≥40 Gy
radiation
Yes 105 79.5% 569 89.9%
p= 0.0008*
No 27 20.5% 64 10.1%
Follow-up time (days) 23.4 42.1 23.3 77.4 p = 0.3284**
*Chi-squared test.
**Mann-Whitney U test (t approximation).
***t-test with equal variances.
†t-test with unequal variances.
‡Mantel-Haenszel chi-squared test for trend.
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nosis with stage 1 disease, compared to unscreened
women treated at the same institution. This downsta-
ging suggests the ORCI screening program is not only
facilitating diagnosis for women with more advanced,
symptomatic disease, but also detection for women with
earlier stage, less symptomatic or asymptomatic disease.
This may be the case for some of the 32 women with
stage 1 disease who were lost to follow-up.
A limitation of the study was the lack of a common
identification number used throughout all records, po-
tentially leading to missed cases in our analysis. Although
a screening clinic serial number partially filled this
purpose, it was not always used in patient records and
was not included in patient log books. Referrals from
screening to treatment were not formally tracked, so a
case definition had to be established based on available
data that may have misclassified some screened women.
Since we only reviewed treatment records at ORCI,
we could not account for the small proportion of
women who may have been treated at institutions in other
countries. Finally, these results may not be generalizable
to screening programs operated distant from cervical can-
cer treatment services.
An important strength of this study is the inclusion of
980 cases of cervical cancer referred from a VIA screening
program over an 8.5 year period, nearly twice the number
of women included in the next largest study [11]. This
sample size permitted evaluation of follow-up and treatment
completion across the diverse demographics served by the
screening clinic, with a wide range of occupations, education
levels, and ages represented. Additionally, most patient and
disease characteristics were measured before follow-up and
treatment. This is the first study to differentiate between
Table 6 Logistic regression of radiation completion among 829 women who followed up for treatment at ORCI
Crude Age-adjusted Age, stage-adj. Final Model**
OR CI OR CI OR CI OR CI
Occupation
Housewife 1 1 1
Manual 0.73 0.37-1.43 0.72 0.36-1.41 0.68 0.34-1.34
Skilled/Other 1.41 0.78-2.57 1.28 0.69-2.36 1.15 0.62-2.14
Education
None 1 1 1
Primary 1.24 0.84-1.84 1.10 0.72-1.68 1.09 0.71-1.67
>Primary 1.04 0.50-2.17 0.88 0.41-1.89 0.75 0.35-1.65
Marital status
Married/regular partner 1 1 1
Widow/separated/other 0.92 0.62-1.35 1.01 0.67-1.51 0.98 0.66-1.48
Last menstrual period
<12 months ago 1 1 1
>12 months ago 0.90 0.62-1.31 1.20 0.75-1.93 1.25 0.77-2.01
Age
Continuous (10 year) 0.88 0.76-1.01 0.89 0.77-1.03 0.87 0.75-1.01
Age at marriage
Continuous 0.98 0.94-1.02 0.97 0.93-1.01 0.97 0.93-1.02
Gravidity
Continuous 1.03 0.97-1.09 1.07 1.00-1.14 1.06 0.99-1.13
Year of first treatment appointment
Continuous (2 year) 0.85 0.73-1.00* 0.85 0.72-1.00* 0.85 0.73-1.00 0.85 0.72-1.00*
Place of residence
Dar es Salaam 1 1 1 1
Other Region 1.40 0.96-2.04 1.48 1.01-2.16 1.44 0.98-2.13 1.46 0.99-2.15
Treatment clinic disease stage
Continuous 0.73 0.55-0.96 0.74 0.56-0.97 0.72 0.55-0.96
Attended another health facility before screening
No 1 1 1
Yes 1.32 0.82-2.11 1.31 0.82-2.10 1.31 0.81-2.11
Prescribed ≥40 Gy radiation***
No 1 1 1
Yes 2.29 1.39-3.75 2.17 1.32-3.59 1.88 1.08-3.25
Follow-up time
Continuous (1 week) 1.00 0.98-1.02 1.00 0.98-1.02 1.00 0.98-1.02
*Significant at the α = 0.05 level, CI includes 1.00 due to rounding.
**Final model adjusted for age, year of first treatment appointment, place of residence, and treatment clinic disease stage.
***Prescribed ≥40 Gy radiation was not included in the final model because it is an intermediate variable between disease stage and radiation completion.
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strated that the factors associated with these outcomes ap-
pear to differ.
Future studies could investigate what proportion of
women diagnosed with invasive cervical cancer at ORCI
screening receives treatment elsewhere. In addition, researchusing patient interviews could help explain the patterns of
follow-up and treatment completion seen in this study.
Conclusions
Our study shows that in addition to detecting and treat-
ing pre-cancerous lesions, a VIA screening program can
Table 7 Factors associated with stage 1 disease among
screened* and unscreened women
Crude Final model**
OR CI OR CI
Screening status
Unscreened 1 1
Screened 1.92 1.22-3.02 1.61 1.01-2.56
Age
Continuous (10 year) 0.79 0.68-0.93 0.83 0.71-0.97
Place of residence
Dar es Salaam 1 1
Other Region 0.50 0.34-0.73 0.59 0.40-0.87
*Disease stage assessed at screening, before any loss to follow-up.
**n = 719 screened and n = 333 unscreened in final model.
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http://www.biomedcentral.com/1471-2458/14/910effectively facilitate diagnosis and timely treatment of in-
vasive cancer. Furthermore, our results offer new insights
into why women with invasive cervical cancer might be
lost to follow-up or fail to complete treatment after being
referred from a VIA screening program in a low-resource
setting. Although they represent a small proportion of
women screened in these programs, women with invasive
disease stand to greatly benefit from proper detection,
diagnosis, and treatment. Consideration of these findings
may improve efforts to intervene before loss to follow-up
and improve outcomes for these women.
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